High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.
High Tech Pharm Co. Ltd (106190) - Net Assets
Latest net assets as of September 2025: ₩126.99 Billion KRW
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has net assets worth ₩126.99 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩139.56 Billion) and total liabilities (₩12.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩126.99 Billion |
| % of Total Assets | 90.99% |
| Annual Growth Rate | 2.66% |
| 5-Year Change | 25.85% |
| 10-Year Change | 23.18% |
| Growth Volatility | 4.91 |
High Tech Pharm Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual net assets of High Tech Pharm Co. Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩119.74 Billion | +11.91% |
| 2023-12-31 | ₩106.99 Billion | +7.06% |
| 2022-12-31 | ₩99.94 Billion | +6.45% |
| 2021-12-31 | ₩93.88 Billion | -1.32% |
| 2020-12-31 | ₩95.14 Billion | -3.49% |
| 2019-12-31 | ₩98.58 Billion | -4.61% |
| 2018-12-31 | ₩103.35 Billion | +1.13% |
| 2017-12-31 | ₩102.19 Billion | +1.00% |
| 2016-12-31 | ₩101.18 Billion | +4.09% |
| 2015-12-31 | ₩97.20 Billion | +5.58% |
| 2014-12-31 | ₩92.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to High Tech Pharm Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 43.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩91.14 Billion | 76.11% |
| Common Stock | ₩5.32 Billion | 4.44% |
| Other Components | ₩23.28 Billion | 19.45% |
| Total Equity | ₩119.74 Billion | 100.00% |
High Tech Pharm Co. Ltd Competitors by Market Cap
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NNIT A/S
LSE:0R5Z
|
$62.94 Million |
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
$62.96 Million |
|
Media Nusantara Citra Tbk PT
JK:MNCN
|
$62.96 Million |
|
flooidCX Corp
PINK:FLCX
|
$62.96 Million |
|
BIOINVENT INTERN. SK 2
F:BIX0
|
$62.93 Million |
|
Lincoln Pharmaceuticals Limited
NSE:LINCOLN
|
$62.93 Million |
|
Cox Energy América, S.A.B. de C.V.
MC:COXE
|
$62.91 Million |
|
Wieson Technologies Co Ltd
TWO:6272
|
$62.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in High Tech Pharm Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 106,994,353,330 to 119,738,277,760, a change of 12,743,924,430 (11.9%).
- Net income of 13,710,010,330 contributed positively to equity growth.
- Dividend payments of 708,878,200 reduced retained earnings.
- Share repurchases of 5,347,500 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩13.71 Billion | +11.45% |
| Dividends Paid | ₩708.88 Million | -0.59% |
| Share Repurchases | ₩5.35 Million | -0.0% |
| Other Changes | ₩-251.86 Million | -0.21% |
| Total Change | ₩- | 11.91% |
Book Value vs Market Value Analysis
This analysis compares High Tech Pharm Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.11x to 1.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩14272.91 | ₩15810.00 | x |
| 2017-12-31 | ₩14416.23 | ₩15810.00 | x |
| 2018-12-31 | ₩14578.89 | ₩15810.00 | x |
| 2019-12-31 | ₩13907.05 | ₩15810.00 | x |
| 2020-12-31 | ₩13421.73 | ₩15810.00 | x |
| 2021-12-31 | ₩13244.16 | ₩15810.00 | x |
| 2022-12-31 | ₩14098.18 | ₩15810.00 | x |
| 2023-12-31 | ₩10062.32 | ₩15810.00 | x |
| 2024-12-31 | ₩11261.43 | ₩15810.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently High Tech Pharm Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.45%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.69%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.17x
- Recent ROE (11.45%) is above the historical average (3.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 8.51% | 13.77% | 0.53x | 1.16x | ₩-1.37 Billion |
| 2015 | 6.73% | 13.61% | 0.43x | 1.15x | ₩-3.18 Billion |
| 2016 | 5.22% | 9.63% | 0.46x | 1.17x | ₩-4.84 Billion |
| 2017 | 2.05% | 3.18% | 0.55x | 1.17x | ₩-8.12 Billion |
| 2018 | 2.52% | 3.93% | 0.50x | 1.29x | ₩-7.73 Billion |
| 2019 | -4.28% | -6.69% | 0.48x | 1.34x | ₩-14.08 Billion |
| 2020 | -3.31% | -4.23% | 0.58x | 1.35x | ₩-12.67 Billion |
| 2021 | -1.31% | -1.67% | 0.60x | 1.31x | ₩-10.61 Billion |
| 2022 | 5.88% | 5.70% | 0.78x | 1.32x | ₩-4.12 Billion |
| 2023 | 7.55% | 10.52% | 0.57x | 1.26x | ₩-2.62 Billion |
| 2024 | 11.45% | 17.69% | 0.55x | 1.17x | ₩1.74 Billion |
Industry Comparison
This section compares High Tech Pharm Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| High Tech Pharm Co. Ltd (106190) | ₩126.99 Billion | 8.51% | 0.10x | $62.94 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |